> Marc-André Gagnon - Centre interdisciplinaire de recherche en développement international et société (CIRDIS) | UQAM

Accueil > Les auteurs > Marc-André Gagnon

Marc-André Gagnon

Note biographique

Marc-André Gagnon est chercheur associé au WHO Collaborating Center on Governance, Accountability and Transparency in the Pharmaceutical Sector. Il détient un doctorat de science politique de l’Université York, un Diplôme d’Études Approfondies en économie de l’École Normale Supérieure de Fontenay/Saint-Cloud et Paris-I Sorbonne, et il a effectué ses études postdoctorales avec le Centre des politiques en propriété intellectuelle de l’Université McGill, ainsi qu’avec le Edmond J. Safra Centre for Ethics à l’Université Harvard. Ses recherches portent sur l’économie politique du secteur pharmaceutique, plus spécifiquement sur l’analyse comparée des régimes d’assurance-santé et d’assurance-médicaments, sur les politiques d’innovation et la propriété intellectuelle dans l’économie des savoirs, de même que sur la corruption institutionnelle dans les secteurs pharmaceutique at biochimique.

Recherche et expertise

– Lead investigator for a SSHRC Insight Grant Catalyst (2021-2026)

Research Topic : Ghost-management in the pharmaceutical and agricultural chemical sectors : Dynamics andimplications for Canadian political economy.

Co-investigators : Louise Vandelac (UQAM) ; Sergio Sismondo (Queens U) ;
Kean Birch (York U).

Collaborators : Cecilia Rikap, Paul Thacker, Catherine Riva and Serena Tinari.

With additional funding from the Initiative for Digital Citizen Research to support the goals of the Government of Canada’s approach to protecting democracy and combatting disinformation and other online harms.

– Fellow with the WHO Collaborating Centre for Governance, Accountability (2016-ongoing) and Transparency in the Pharmaceutical Sector

– Co-investigator for a Jean-Monnet Networks Grant (2019-2021)

To Build capacity on the study Of European Health Policy. With Katherine Fierlbeck and Tom Jefferson, Marc-Andre Gagnon focuses on Regulation and Transparency in Pharmaceutical Policy. The Summer School organized in May-June 2020 was cancelled due to the pandemic.

Enseignements et expériences professionnelles

Professeur invité :

July 2016 - July 2017 : University of Ottawa : Visiting Professor with the Centre on Health Law, Policy and Ethics.

Summer 2014 : Université Montesquieu Bordeaux-IV (France) : Visiting Professor with the Groupe de Recherche en Économie Théorique et Appliquée.

À l’Université Carleton :

– PhD course in public policy :
PADM 6010 : Current Issues in Public Policy (Fall 2020, Fall 2021)

Graduate courses in public policy :

– PADM 5672 : Policy Seminar on Pharmaceutical Policy (Summer 2012, 2013, 2015, Fall 2018, Winter 2020)

– PADM 5228 : Social Policy (Summer 2011, Winter 2012, Fall 2012, Fall 2013, Fall 2015, Fall 2017, Fall 2019, Winter 2021)

– PADM 5129 : Capstone Seminar (Winter 2018, Winter 2019, Winter 2020, Winter 2021)

– PADM 5120 : Modern Challenges to Governance (Fall 2020)

– PADM 5115 : Intro to State and Society (Winter 2011, Fall 2011, Winter 2012, Winter 2013, Winter 2014 (twice), Winter 2015 (twice), Fall 2015, Winter 2016)

Graduate course in political economy :

– PECO 5001 : Methodology in Political Economy (Winter 2018, Winter 2019)

Undergraduate course with Arthur Kroeger College of Public Affairs :

– PAPM 1000 : Introduction to public affairs and policy management : History of economic thought (Winter 2013, Winter 2014, Winter 2015, Winter 2016, Winter 2018, Winter 2019, Winter 2020)

À l’Université de Bordeaux-IV :

Cour de doctorat en économie pour le Groupe de Recherche en Économie Théorique et Appliquée : Capital, science et pouvoir : les dynamiques d’accumulation dans l’économie du savoir (Été 2014).

À l’Université McGill :

Graduate course at Faculty of Law : CMPL 605 : Regulation, Technology and Society (Winter 2010)

À l’Université du Québec à Montréal :

Cours de Maîtrise : POL 8010 : Théorie du politique (Automne 2007, Political Science, Université du Québec à Montréal)

Prix et bourses

– Public Commentary Award, Faculty of Public Affairs, Carleton University, 2015

– Ethel Meade Award for Excellence in Healthcare Research, from Ontario Health Coalition, 2014

– “Rising Star Award” from the Institute of Health Services and Policy Research, 2010

– Yumiko Iida Memorial PhD Prize for best dissertation in political science, 2010

– Excellence Award by the Union of Lecturers at University of Montreal, 2008

Ouvrages Articles scientifiques Études, mémoires et thèses et Communications Articles de journaux et médias en ligne Dans les médias Conférences

Articles scientifiques

Études, mémoires et thèses et Communications

Chroniques

Articles de journaux et médias en ligne

Autres publications

Conférence : Le gouvernement de l’Union européenne revisité : l’éclipse du « dirigisme communautaire »

Marc-André Gagnon, Michèle Rioux, 3 avril 2023
Articles scientifiques

– Testoni FE, García Carrillo M, Gagnon M-A, Rikap C, Blaustein M (2021) Whose shoulders is health research standing on ? Determining the key actors and contents of the prevailing biomedical research agenda. PLoS ONE 16(4) : e0249661. https://doi.org/10.1371/journal.pone.0249661: 1-17.

– Lexchin J, Bero LA, Davis C, Gagnon MA. Achieving greater independence from commercial influence in research. BMJ. 2021 Mar 9 ;372 : n370. doi : 10.1136/bmj.n370. PMID : 33687982.

– Gagnon MA (2020). Understanding the Battle for Universal Pharmacare in Canada ; Comment on “Universal Pharmacare in Canada”. International Journal of Health Policy and Management. Vol. 10 (3) March 2021 : pp.168-171, doi : 10.34172/ijhpm.2020.40

– Deborah Gleeson (Principal author), Joel Lexchin, Ronald Labonte, Belinda Townsend, MA Gagnon, Jillian Kohler, Lisa Forman and Ken Shadle. “Analysing the impact of trade and investment agreements on pharmaceutical policy : provisions, pathways and potential impacts”. Globalization and Health 15(1), November 2019 : 1-17.

– Charbonneau, Mathieu, MA Gagnon. « Surviving niche busters : Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs ». Health Policy 122 (12). December 2018 : 1295-1301.

– Lexchin, J, JC Kohler, MA Gagnon, J Crombie, P Thacker, A Shnier. “Combating corruption in the pharmaceutical arena. Indian Journal of Medical Ethics, March 15 2018 : 1-6.

– Morgan, Steven G, Marc-André Gagnon, Mathieu Charbonneau, Alain Vadeboncoeur. “Evaluating the effects of Quebec’s private– public drug insurance system”. Canadian Medical Association Journal 189 (40) ; Oct 10, 2017 : E1259-E1263.

– Gagnon, MA (principal author) and Karena Volesky, 2017. “Merger Mania : Mergers and acquisitions in the generic drug sector from 1995 to 2016”. Globalization and Health. 13 (62) : 1-7.

– Morgan, Steven G., MA Gagnon, Barbara Mintzes and Joel Lexchin, 2016. “A Better Prescription : Advice for a National Strategy on Pharmaceutical Policy in Canada”. Healthcare Policy 12 (1), May 2016.

– Gagnon, MA, 2015. “New Drug Pricing ; Does it make any sense ?” Prescrire International 24 (162) : 192-195. English translation of Gagnon, MA, 2015. « Pourquoi les médicaments sont-ils si chers ? Les dérives d’un modèle d’affaires. » Prescrire 35 (380) : 457-461.

– Lexchin, Joel and MA Gagnon, 2014. « CETA and pharmaceuticals : impact of the trade agreement between Europe and Canada on the costs of prescription drugs ». Globalization and Health, Vol. 10 #30, May 2014.
Gagnon, MA, 2013. “Corruption of Pharmaceutical Markets : Addressing the Misalignment of Financial Incentives and Public Health,” in Journal of Law, Medicine and Ethics, Vol. 41 #3, September 2013 : 571-580.

– Gagnon, MA, 2012. “Corporate influence over clinical research : Considering the
alternatives.” Prescrire International 21(129) : 191-194. English translation of Gagnon, MA, 2012. “Recherche Clinique Sous Influence : Penser les Alternatives.” Prescrire (342) (March 2012) : 311-314.

– Gagnon, MA, 2012. “L’Aide Publique à L’Industrie Pharmaceutique Québécoise : le
jeu en vaut-il la Chandelle ?” Interventions Economiques/Papers in Political Economy
(44) : 1-17.

– Gagnon, MA (principal author) and Joel Lexchin, 2008. “The Cost of Pushing Pills : A
New Estimate of Pharmaceutical Promotion Expenditures in the United States.” PLoS Medicine 5(1) : 1-6.

– Gagnon, MA, 2007. “Capital, Power & Knowledge according to Thorstein Veblen :
Reinterpreting the Knowledge-Based Economy.” Journal of Economic Issues 41(2) : 593-
600.

Chapitres de livres

– Gagnon, MA, 2021. "Ghost management as a central feature of accumulation in corporate capitalism : the case of the global pharmaceutical sector". Chapter from Marlène Benquet and Théo Bourgeron (ed.) Accumulating Capital Today : Contemporary Strategies of Profit and Dispossessive Policies. New York : Routledge : pp.163-177.

– Gagnon, MA, Matthew Herder, Janice Graham, Katherine Fierlbeck and Anna Danyliuk, 2021. “Clinical trial data transparency in Canada : Mapping the Progress from Laggard to Leader”. Chapter from Katherine Fierlbeck, Janice Graham and Matthew Herder (eds.) Transparency, Power, and Influence in the Pharmaceutical Industry. Toronto : University of Toronto Press : pp. 114-128.

– Gagnon, MA, 2021. “The Political Economy of Influence ; Ghost-management in the Pharmaceutical Sector”. Chapter from Katherine Fierlbeck, Janice Graham and Matthew Herder (eds.) Transparency, Power, and Influence in the Pharmaceutical Industry. Toronto : University of Toronto Press : pp. 159-183.

– Gagnon, MA, 2017. « Financing the Public Provision of Prescription Drugs in Canada : Comparison and Assessment of Financing Options » in Katherine Graham and Allan Maslove (eds) How Ottawa Spends 2017-2018 ; Canada@150. Ottawa : Carleton University, October 2017.

– Gagnon, MA, 2016. “Shaping the social determinants of value through economic ghostmanagement : an institutionalist approach to capital accumulation.” Published in Tae-Hee Jo and Frederic S. Lee (eds). Marx, Veblen, and the Foundations of Heterodox Economics : Essays in Honor of John F. Henry. London and New York : Routledge : pp.228-251.

– Gagnon, MA (principal author) and Dimitri della Faille, 2013. “Thorstein Veblen :
Economista Iconoclasta.” Published in P.P. Poggio (dir.) L’altronovecento. Comunismo eretico e pensiero critico. Vol 3 : Il Capitalismo Americano E I Suoi Critici. Milano : Jaca Book.

– Gagnon, MA, 2012. “Les Droits de Propriété Intellectuelle sont-ils un écueil pour la modernité industrielle ? La cas des brevets dans l’industrie pharmaceutique” in Marie-Pierre Boucher (dir.) La Propriété et ses Multiples. Montreal : Nota Bene : 201-250.

– Gagnon, MA, 2004. “La main visible de la propriété intellectuelle contre l’intérêt général : Les formes disciplinaires du néolibéralisme,” in La Régulation Néolibérale : Crise ou ajustement ?” Edited by Raphael Canet and Jules Duchastel. Montreal : Athéna Éditions ; pp.175-200.

– Gagnon, MA, 2002. “Mercantilisme,” in Relations Internationales : Théories et Concepts. Ed. Évelyne Dufault, Guillaume Dufour, and Alex MacLeod. Montréal : Athéna Éditions ; 128-130.

– Gagnon, MA, 2000. “Les réseaux de l’internationalisme statistique (1885-1914),” in Jean-Pierre Beaud and Jean-Guy Prévost (dir.) L’ère des chiffres : systèmes statistiques et traditions nationales. Québec : Presses de l’Université du Québec ; 181-220.

Rapports

– MA Gagnon. La régulation des prix des médicaments au Canada et au Québec. Document préparé dans le cadre de la poursuite Merck Canada Inc. c. Procureur général du Canada. Document soumis au procureur général du Canada, 13 mars 2020.

– MA Gagnon (principal author) and Sidney Wolfe. 2015. Mirror, Mirror on the Wall : Medicare Part D pays needlessly high brand-name drug prices compared with other OECD countries and with U.S. government programs. Report for Public Citizen and Carleton University’s School of Public Policy and Administration. Policy Brief, July 23 2015 : 19 p. : https://carleton.ca/sppa/wp-content/uploads/Mirror-Mirror-Medicare-Part-D-Released.pdf.

Steven G. Morgan, Danielle Martin, MA Gagnon, Barbara Mintzes, Jamie R. Daw and Joel Lexchin. 2015. Pharmacare 2020 ; The Future of Drug Coverage in Canada. Published by the Pharmaceutical Policy Research Collaboration, University of British Columbia. July 15 2015 : https://pharmacare2020.ca/learn-more

– MA Gagnon. A Roadmap to Rational Pharmacare Policy in Canada. Ottawa : Canadian Federation of Nurses Unions. August 2014. : https://nursesunions.ca/wp-content/uploads/2017/05/Pharmacare_FINAL.pdf
MA Gagnon (principal author) and Guillaume Hébert. “The Economic Case for
Universal Pharmacare.” Ottawa : IRIS and CCPA, September 2010 : https://www.policyalternatives.ca/publications/reports/economic-case-universal-pharmacare.